Merck KGaA, Newron start phase III study on Safinamide to treat Parkinson's (FinanzNaInformation on Merck KGaA, Newron start phase III study on Safinamide to treat Parkinson's (FinanzNa under Parkinson's section of the Health Articles & Reviews; DARMSTADT, Germany (Thomson Financial) - Merck KGaA ( Nachrichten / Aktienkurs ) said it started a phase III trial to test the drug Safinamide, which ... |
![]() |
|
Merck KGaA, Newron start phase III study on Safinamide to treat Parkinson's (FinanzNa
by A F Boyle 12-01-2007, 10:22 PM
DARMSTADT, Germany (Thomson Financial) - Merck KGaA ( Nachrichten / Aktienkurs ) said it started a phase III trial to test the drug Safinamide, which it is developing with partner Newron Pharmaceuticals SpA, ( Nachrichten ) for the treatment of Parkinson's disease.
More... |
|
Views 33
Comments 0
|
![]() |
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |